Jason Butler
Stock Analyst at JMP Securities
(4.03)
# 627
Out of 4,667 analysts
130
Total ratings
45.45%
Success rate
13.89%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jason Butler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SYRS Syros Pharmaceuticals | Downgrades: Market Perform | n/a | $0.29 | - | 4 | Nov 13, 2024 | |
| HALO Halozyme Therapeutics | Maintains: Market Outperform | $72 → $73 | $45.76 | +59.53% | 13 | Nov 1, 2024 | |
| ARGX argenx SE | Maintains: Market Outperform | $497 → $606 | $591.82 | +2.40% | 6 | Nov 1, 2024 | |
| MRNS Marinus Pharmaceuticals | Downgrades: Market Perform | n/a | $0.31 | - | 3 | Oct 24, 2024 | |
| AQST Aquestive Therapeutics | Reiterates: Market Outperform | $9 | $4.74 | +90.07% | 7 | Oct 8, 2024 | |
| ZVRA Zevra Therapeutics | Initiates: Market Outperform | $17 | $8.97 | +89.52% | 1 | Sep 24, 2024 | |
| RZLT Rezolute | Reiterates: Market Outperform | $7 | $5.01 | +39.72% | 7 | Sep 20, 2024 | |
| GHRS GH Research | Reiterates: Market Outperform | $39 | $10.95 | +256.16% | 4 | Sep 4, 2024 | |
| CYTK Cytokinetics | Reiterates: Market Outperform | $78 | $49.86 | +56.44% | 12 | Sep 4, 2024 | |
| ATHA Athira Pharma | Downgrades: Market Perform | n/a | $0.64 | - | 7 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $14 → $7 | $0.84 | +736.62% | 7 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $50 → $23 | $2.72 | +745.59% | 3 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $85 → $83 | $14.40 | +476.39% | 7 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $23 | $3.05 | +654.10% | 3 | Apr 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $19 | $10.74 | +76.91% | 6 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $44 → $39 | $16.27 | +139.70% | 13 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $42 → $38 | $19.79 | +92.02% | 7 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $22 | $3.52 | +525.00% | 1 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.12 | - | 1 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $1,200 | $0.63 | +191,715.86% | 1 | Dec 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $111 → $116 | $9.08 | +1,177.53% | 4 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $9 | $3.44 | +161.63% | 1 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $191 → $111 | $2.41 | +4,505.81% | 6 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.04 | - | 1 | Dec 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $24 → $21 | $85.64 | -75.48% | 5 | Aug 8, 2019 |
Syros Pharmaceuticals
Nov 13, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $0.29
Upside: -
Halozyme Therapeutics
Nov 1, 2024
Maintains: Market Outperform
Price Target: $72 → $73
Current: $45.76
Upside: +59.53%
argenx SE
Nov 1, 2024
Maintains: Market Outperform
Price Target: $497 → $606
Current: $591.82
Upside: +2.40%
Marinus Pharmaceuticals
Oct 24, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $0.31
Upside: -
Aquestive Therapeutics
Oct 8, 2024
Reiterates: Market Outperform
Price Target: $9
Current: $4.74
Upside: +90.07%
Zevra Therapeutics
Sep 24, 2024
Initiates: Market Outperform
Price Target: $17
Current: $8.97
Upside: +89.52%
Rezolute
Sep 20, 2024
Reiterates: Market Outperform
Price Target: $7
Current: $5.01
Upside: +39.72%
GH Research
Sep 4, 2024
Reiterates: Market Outperform
Price Target: $39
Current: $10.95
Upside: +256.16%
Cytokinetics
Sep 4, 2024
Reiterates: Market Outperform
Price Target: $78
Current: $49.86
Upside: +56.44%
Athira Pharma
Sep 4, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $0.64
Upside: -
Aug 15, 2024
Maintains: Market Outperform
Price Target: $14 → $7
Current: $0.84
Upside: +736.62%
Jul 26, 2024
Maintains: Market Outperform
Price Target: $50 → $23
Current: $2.72
Upside: +745.59%
May 9, 2024
Maintains: Market Outperform
Price Target: $85 → $83
Current: $14.40
Upside: +476.39%
Apr 19, 2024
Reiterates: Market Outperform
Price Target: $23
Current: $3.05
Upside: +654.10%
Apr 9, 2024
Reiterates: Market Outperform
Price Target: $19
Current: $10.74
Upside: +76.91%
Mar 12, 2024
Maintains: Outperform
Price Target: $44 → $39
Current: $16.27
Upside: +139.70%
Nov 14, 2023
Maintains: Market Outperform
Price Target: $42 → $38
Current: $19.79
Upside: +92.02%
Sep 28, 2023
Initiates: Market Outperform
Price Target: $22
Current: $3.52
Upside: +525.00%
Oct 17, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $2.12
Upside: -
Dec 15, 2021
Initiates: Market Outperform
Price Target: $1,200
Current: $0.63
Upside: +191,715.86%
Nov 23, 2021
Maintains: Market Outperform
Price Target: $111 → $116
Current: $9.08
Upside: +1,177.53%
Nov 8, 2021
Maintains: Market Outperform
Price Target: $7 → $9
Current: $3.44
Upside: +161.63%
May 5, 2021
Maintains: Market Outperform
Price Target: $191 → $111
Current: $2.41
Upside: +4,505.81%
Dec 2, 2020
Downgrades: Market Perform
Price Target: n/a
Current: $1.04
Upside: -
Aug 8, 2019
Reiterates: Market Outperform
Price Target: $24 → $21
Current: $85.64
Upside: -75.48%